Actinium Pharmaceuticals, Short Interest Update

Trending News ☀️

Actinium Pharmaceuticals ($NYSEAM:ATNM), Inc. is a biopharmaceutical company that develops targeted therapies for cancer. The company’s products are based on its proprietary Antibody-Targeted Alpha-Particle Immunotherapy platform. ATAC is designed to kill cancer cells with minimal damage to healthy tissue. Actinium Pharmaceuticals has seen an increase in short interest in recent months. This may be due to the company’s recent clinical successes, including the FDA approval of its lead product, Iomab-B, for the treatment of relapsed or refractory acute myeloid leukemia .

The FDA’s decision was based on data from the Phase 3 SIERRA trial, which showed that Iomab-B improved survival in patients with relapsed or refractory AML. In addition to its clinical successes, Actinium Pharmaceuticals has also made significant progress in manufacturing and commercialization. The company recently completed a new state-of-the-art manufacturing facility and has partnered with several leading distributors in the United States. With its strong clinical and commercial progress, Actinium Pharmaceuticals is well positioned for continued success in the coming years.

Share Price

Actinium Pharmaceuticals, Inc. saw a significant increase in short interest in the month of January. The stock has risen by 6.8% in the past week. The majority of the media coverage on Actinium Pharmaceuticals has been positive in recent months. On Tuesday, the stock opened at $7.50 and closed at $7.90, a rise of 6.8% from the prior closing price of $7.40.

Actinium Pharmaceuticals is engaged in the development of targeted therapies for cancer. The Company’s lead product candidate, Iomab-B, is an antibody-radiation conjugate that is in development for conditioning patients prior to a hematopoietic stem cell transplant, commonly referred to as a bone marrow transplant. Actinium Pharmaceuticals is headquartered in New York, New York.

VI Analysis

According to VI Risk Rating, Actinium Pharmaceuticals is a medium risk investment in terms of financial and business aspects. The company’s financial risk is due to its reliance on a small number of products in development and its need for additional financing to fund operations and clinical trials. The company’s business risk is due to the uncertain efficacy and safety of its products, the lengthy and expensive process of drug development and commercialization, and the competitive landscape in the pharmaceutical industry.

VI App has detected 3 risk warnings in income sheet, balance sheet, cashflow statement. Register on vi.app to check it out.

Summary

Actinium Pharmaceuticals, Inc. saw a significant increase in short interest in the month of August. The stock price of ATNM moved up the same day. Investors are positive about the company’s future prospects.

The company has a good chance of growing its earnings and revenue in the future. The stock is a good investment at its current price.